HDAC3 Silencing Enhances Acute B Lymphoblastic Leukaemia Cells Sensitivity to MG-132 by Inhibiting the JAK/Signal Transducer and Activator of Transcription 3 Signaling Pathway
Conclusions: Silencing of HDAC3 enhanced the sensitivity of B-ALL cells to MG-132. The combination of targeting HDAC3 and MG-132 may provide a new avenue for clinical treatment of acute B lymphocytic leukaemia and improve the poor survival of leukaemia patients.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - September 23, 2020 Category: Cancer & Oncology Source Type: research

White Blood Cell Count Nadir and Duration of Aplasia Do Not Associate with Treatment Outcome in Adult Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy
Discussion: The present study evaluated the potential prognostic role of WBC count nadir and duration of aplasia, demonstrating that they are not associated with treatment outcomes in adult patients with AML treated with intensive chemotherapy. Therefore, a short duration of aplasia seems not linked to poor therapeutic efficacy in clearing bone marrow blasts. Our findings, although needing validation in larger and more homogeneous cohorts, may offer helpful clues in the management of aplasia of AML patients.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - September 18, 2020 Category: Cancer & Oncology Source Type: research

Predictors of Response and Survival Outcomes of Triple Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Conclusions: Insights into the chemo-resistance mechanisms and exploration of novel targeted agents in subgroups as per AR and Ki-67 status are needed to improve survival outcomes in TNBC patients.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - September 7, 2020 Category: Cancer & Oncology Source Type: research

A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis
In this study, we prospectively evaluated the usefulness of CYP2C19 polymorphism analysis in adjusting the initial VRCZ maintenance dose. The study enrolled 19 patients who underwent analysis of CYP2C19 polymorphism prior to VRCZ administration. Subjects were classified into 3 phenotype subgroups: extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM). The initial VRCZ maintenance doses given twice daily were proposed as follows: approximately 8, 6, and 4 mg/kg/day for EM, IM and PM, respectively, according to previous reports. In EM, the initial maintenance dose was 8.0 ± 0.5 mg/kg/day...
Source: Chemotherapy - September 2, 2020 Category: Cancer & Oncology Source Type: research

Publisher's Note
Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - September 1, 2020 Category: Cancer & Oncology Source Type: research

Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Conclusions: We developed a highly sensitive and selective HPLC-MS/MS method to quantify PNT in human plasma. This method might be used for TDM and to guide dose reductions if unnecessary high PNT levels are detected in a patient.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - August 21, 2020 Category: Cancer & Oncology Source Type: research

High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature
Basal cell carcinoma is the most common skin tumour, with the majority of the cases occurring on the head and neck district, where cosmetic and functional results are crucial. It can be locally destructive if not diagnosed early and treated appropriately. Surgery is the treatment of choice for most lesions, but aggressive, recurrent, or unresectable tumours can be challenging to manage. Advanced basal cell carcinoma includes high recurrence risk subtypes, in which standard therapies demonstrate lack of efficacy. This led to a need for investigating more deeply the pathogenesis of the disease and to the discovery of the imp...
Source: Chemotherapy - August 10, 2020 Category: Cancer & Oncology Source Type: research

Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice
Conclusions: MT supplementation to cytotoxic drugs can improve antitumor response, especially if it is blunted because of an inappropriate time of administration.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - August 7, 2020 Category: Cancer & Oncology Source Type: research

Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer
Conclusions: Nab-PTX may be a later-line chemotherapeutic option for previously treated advanced NSCLC.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - July 16, 2020 Category: Cancer & Oncology Source Type: research

Risk Associated with Severe Hematological Toxicity in Patients with Urothelial Cancer Receiving Combination Chemotherapy of Gemcitabine and Cisplatin
Conclusions: PS ≥ 1, neutrophil count, PLT, andK level were important risk factors for GC therapy-induced hematological toxicity in patients with UC. To continue GC therapy, further management systems by hematological toxicity risk factors for patients with UC will be required.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - July 15, 2020 Category: Cancer & Oncology Source Type: research

Contents Vol. 64, 2019
Chemotherapy 2019;64:I –V (Source: Chemotherapy)
Source: Chemotherapy - July 7, 2020 Category: Cancer & Oncology Source Type: research

Acknowledgement to Reviewers
Chemotherapy 2019;64:270 (Source: Chemotherapy)
Source: Chemotherapy - July 7, 2020 Category: Cancer & Oncology Source Type: research

Rare Case of Endoscopic Treatment for Bevacizumab-Related Gastric Perforation in a Patient with Ovarian Cancer
We present a rare case of bevacizumab-induced gastric perforation in a patient with advanced OC occurred during bevacizumab-including chemotherapy in an adjuvant setting. Surgical treatment was not possible due to the frailty of the clinical condition of the patient and the gastric perforation was successfully treated with endoscopic suturing.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - July 2, 2020 Category: Cancer & Oncology Source Type: research

Sustained Complete Remission with Incomplete Hematologic Recovery (CRi) in a Patient with Relapsed AML and Concurrent BCR-ABL1 and CBFB Rearrangement Treated with a Combination of Venetoclax and 5-Azacytidine
The co-occurrence ofBCR-ABL1 fusion and core-binding factor (CBF) rearrangements is uncommonly reported in AML. Although CBF rearrangements carry a favorable prognosis, the coexistence ofBCR-ABL1 is associated with aggressive disease suggesting a potential advantage of high-intensity chemotherapy in association with tyrosine kinase inhibitors. Herein, we describe a refractory AML patient harboringBCR-ABL1 fusion and CBFB rearrangement that was successfully treated with a combination of venetoclax and hypomethylating agent.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - June 22, 2020 Category: Cancer & Oncology Source Type: research

Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials
Conclusions: PF and PS show similar antitumor efficacy (OS, PFS, ORR, and DCR), but patients receiving PS exhibit longer TTF and fewer AEs (stomatitis, nausea, and hypokalemia) than those receiving PF.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - June 12, 2020 Category: Cancer & Oncology Source Type: research

When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia
Arsenic has been known for centuries for its double-edged potential: a poison and at the same time a therapeutic agent. The name “arsenikon,” meaning “potent,” speaks itself for the pharmaceutical properties of this compound, questioned and analyzed for at least 2000 years. In the last decades, acute promyelocytic leukemia (APL) has evolved from a highly fatal to a curable disease, due to the use of all-trans-retinoic acid and, more recently, arsenic trioxide combinations. The success of these entirely chemo-free regimens increased the awareness of APL and reduced the prevalence of early deaths, whi...
Source: Chemotherapy - June 10, 2020 Category: Cancer & Oncology Source Type: research

The First Report on Pharmacokinetic/Pharmacodynamic Study of Trimethoprim/Sulfamethoxazole against < b > < i > Staphylococcus aureus < /i > < /b > with a Neutropenic Murine Thigh Infection Model
Conclusions: The TMP/SMX treatment demonstrated that the free AUC/MIC of SMX was the better predictor of the PK/PD index of TMP/SMX.Chemotherapy 2019;64:224 –232 (Source: Chemotherapy)
Source: Chemotherapy - May 20, 2020 Category: Cancer & Oncology Source Type: research

Erratum
Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - May 19, 2020 Category: Cancer & Oncology Source Type: research

Exploring the Role of Piperacillin and Tazobactam in Combination with Vancomycin against Methicillin-Resistant < b > < i > Staphylococcus aureus < /i > < /b >
Previous studies have demonstrated synergy between piperacillin (PIP)-tazobactam (TAZ) (TZP) and vancomycin (VAN) against methicillin-resistantStaphylococcus aureus (MRSA). However, it is unknown whether PIP and/or TAZ synergizes with VAN against MRSA. We sought to determine whether PIP and/or TAZ synergizes with VAN against MRSA in vitro. The activity of PIP and/or TAZ with and without VAN (1/2 the minimum inhibitory concentration) was tested against 5 clinical MRSA isolates using a 24-h time-kill methodology. Antibiotic susceptibilities, accessory gene regulator (agr) operon functionality, and US strain type were also de...
Source: Chemotherapy - May 12, 2020 Category: Cancer & Oncology Source Type: research

Stereotactic Body Radiotherapy Combined with Transcatheter Arterial Chemoembolization versus Stereotactic Body Radiotherapy Alone as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review
Conclusion: SBRT + TACE appears to be more effective than SBRT alone in treating unresectable HCC. However, its higher incidence rate of leukopenia and fever need to be monitored.Chemotherapy 2019;64:248 –258 (Source: Chemotherapy)
Source: Chemotherapy - April 22, 2020 Category: Cancer & Oncology Source Type: research

Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study
Conclusion: Cetuximab plus radiotherapy appears to be feasible and active in elderly patients unsuitable for cisplatin treatment. The treatment was supported by a favorable toxicity profile.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - June 26, 2019 Category: Cancer & Oncology Source Type: research

Essential Oils for the Treatment of Herpes Simplex Virus Infections
Infections with herpes simplex virus type (HSV)-1 and HSV-2 are distributed worldwide. Although standard therapies with acyclovir and other synthetic drugs are available, the safety and efficacy of these drugs are limited due to the development of drug resistance and adverse side effects. The literature on essential oils and isolated compounds was reviewed regarding their antiviral activities against HSV-1 and HSV-2. The present overview aims to review experimental data and clinical trials focusing on the antiviral activity of selected essential oils and isolated oil components. HSV was found to be susceptible to many esse...
Source: Chemotherapy - June 24, 2019 Category: Cancer & Oncology Source Type: research

Inhibition of Pantothenate Synthetase by Analogs of β-Alanine Precursor Ineffective as an Antibacterial Strategy
Conclusions: Upon revision of the literature, we conclude that high enzyme selectivity or external salvage mechanisms may render this strategy futile against most bacteria.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - June 5, 2019 Category: Cancer & Oncology Source Type: research

Pharmacokinetics of Benzylpenicillin (Penicillin G) during Prolonged Intermittent Renal Replacement Therapy
Prolonged intermittent renal replacement therapy (PIRRT) is an increasingly adopted method of renal replacement in critically ill patients. Like continuous renal replacement therapy, PIRRT can alter the pharmacokinetics (PK) of many drugs. In this setting, dosing data for antibiotics like benzylpenicillin are lacking. In order to enable clinicians to prescribe benzylpenicillin safely and effectively, knowledge of the effects of PIRRT on the plasma PK of benzylpenicillin is required. Herein, we describe the PK of benzylpenicillin in 2 critically ill patients on PIRRT for the treatment of penicillin-susceptibleStaphylococcus...
Source: Chemotherapy - June 5, 2019 Category: Cancer & Oncology Source Type: research

Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Conclusion: Combined ACT-D+MTX chemotherapy achieved overall better efficacy and showed less toxicity than ACT-D or MTX alone, and thus can be prioritized for the treatment of LR-GTN.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - June 4, 2019 Category: Cancer & Oncology Source Type: research

Gonadal Function Recovery and Fertility in Women Treated with Chemo- and/or Radiotherapy for Hodgkin ’s and Non-Hodgkin Lymphoma
Conclusions: This study suggests a possible role of pharmacological prophylaxis with OCs and GnRH analogues.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - May 22, 2019 Category: Cancer & Oncology Source Type: research

Levofloxacin for NIH Category II Chronic Bacterial Prostatitis: A Real-Life Study
Conclusion: Levofloxacin retained its therapeutic efficacy in patients assessed in a real-life setting, and high eradication rates were attained when it was administered as a single agent. A combination of an FQ with azithromycin induced a significant improvement of eradication rates. This strategy may be an interesting option in both first-referral and relapsing cases, although caution should be exercised when patients are at risk of developing arrhythmias, tendinitis, or other adverse effects.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - May 21, 2019 Category: Cancer & Oncology Source Type: research

Acknowledgement to Reviewers
Chemotherapy 2018;63:352 (Source: Chemotherapy)
Source: Chemotherapy - May 5, 2019 Category: Cancer & Oncology Source Type: research

Contents Vol. 63, 2018
Chemotherapy 2018;63:I –VI (Source: Chemotherapy)
Source: Chemotherapy - May 5, 2019 Category: Cancer & Oncology Source Type: research

< b > < i > IL1RN < /i > < /b > Polymorphisms Are Associated with a Decreased Risk of Esophageal Cancer Susceptibility in a Chinese Population
Conclusions: Our study provided the first evidence thatIL1RN rs3181052, rs452204, and rs315919 are correlated with a decreased risk of esophageal cancer in a Northwest Han Chinese population. These findings may be useful for the development of early prognostics for esophageal cancer. However, further larger studies on different ethnic populations are warranted to verify these findings.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - April 17, 2019 Category: Cancer & Oncology Source Type: research

Cancer Therapy-Related Cardiac Dysfunction: Are We Treating Echocardiograms, Patients, Neither, or Both?
Chemotherapy 2018;63:338 –339 (Source: Chemotherapy)
Source: Chemotherapy - April 15, 2019 Category: Cancer & Oncology Source Type: research

Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review
In conclusion, with the present case report, we confirm ruxolitinib efficacy in reducing bone marrow fibrosis grade and assume its possible role in the resolution of osteolytic lesions in PMF. Obviously, further studies with a greater number of patients are needed to document the exact frequency of these unusual findings and the possible role of ruxolitinib in their treatment.Chemotherapy 2018;63:340 –344 (Source: Chemotherapy)
Source: Chemotherapy - April 15, 2019 Category: Cancer & Oncology Source Type: research

Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible < b > < i > Staphylococcus aureus < /i > < /b > Bloodstream Infections
Conclusions: Among nafcillin- or cefazolin-treated patients with MSSA BSI, there was no significant difference in treatment failure. Observing more frequent presumptive adverse effects associated with nafcillin receipt, future prospective studies evaluating cefazolin appear warranted.Chemotherapy 2018;63:345 –351 (Source: Chemotherapy)
Source: Chemotherapy - April 15, 2019 Category: Cancer & Oncology Source Type: research

Comparative Emergence of Resistance to Clofoctol, Erythromycin, and Amoxicillin against Community-Acquired Bacterial Respiratory Tract Pathogens in Italy
In this study, we focused on clo ­foctol and aimed to verify the emergence of clofoctol resistance over time. Additionally, the ability of clofoctol to induce resistance under static and dynamic conditions was evaluated. The minimum inhibitory concentration (MIC) values measured in pathogens isolated from 1990 to 1995 were compare d to those isolated from 2017 to 2018. The behaviour of clofoctol is similar to that of amoxicillin, while erythromycin shows a different behaviour with an increase in MIC. A rapid decline in CFUs with complete eradication at 96 and 120 h in the case of clofoctol and amoxicillin, respectively...
Source: Chemotherapy - March 25, 2019 Category: Cancer & Oncology Source Type: research

Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor
Conclusion: IM Cmin at steady state was significantly associated with body weight and body surface area. Monitoring of IM Cmin might be particularly important for the optimal treatment with IM of male patients and those who have undergone gastrectomy.Chemotherapy 2018;63:301 –307 (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2019 Category: Cancer & Oncology Source Type: research

Overexpression of TEL-MN1 Fusion Enhances Resistance of HL-60 Cells to Idarubicin
Conclusion: Taken together, our results indicated that TEL-MN1 fusion is an oncogene involved in the leukemogenesis process and TEL-MN1 overexpression enhanced resistance of HL-60 cells to idarubicin, which may provide a useful tool for studying the mechanism of leukemogenesis and drug resistance.Chemotherapy 2018;63:308 –314 (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2019 Category: Cancer & Oncology Source Type: research

Ivabradine in Cancer Treatment-Related Left Ventricular Dysfunction
Conclusions: The ability to improve symptoms and LVEF in unfit cancer patients makes ivabradine a reasonable pharmacological tool for treating CTrLVD.Chemotherapy 2018;63:315 –320 (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2019 Category: Cancer & Oncology Source Type: research

Use of Rifabutin as an Alternative Agent for Human Brucellosis: A Case Report
We present a case that developed intolerance to many anti-brucella drugs, who was then successfully treated with a combination of rifabutin, ofloxacin, and ceftriaxone.Chemotherapy 2018;63:321 –323 (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2019 Category: Cancer & Oncology Source Type: research

False Positive Cardiotoxicity Events in Cancer-Related Clinical Trials: Risks Related to Imperfect Noninvasive Parameters
Conclusion: A 3.60% false positive rate in trials where the expected level of toxicity is low suggests that false positives are troubling and may exceed true positive results. Strategies to reduce the number of false positive results include making confirmatory studies mandatory. Evaluating increases along with decreases obtains some estimation of variance.Chemotherapy 2018;63:324 –329 (Source: Chemotherapy)
Source: Chemotherapy - March 7, 2019 Category: Cancer & Oncology Source Type: research

Selective MMP Inhibition, Using AZD3342, to Reduce Gastrointestinal Toxicity and Enhance Chemoefficacy in a Rat Model
Conclusions: This study showed partial efficacy of AZD3342 in reducing tumor growth and delaying the onset of severe diarrhea caused by MTX in rats. We suggest further studies be undertaken targeting appropriate scheduling of AZD3342 as well as investigating different cytotoxic therapies that strongly activate MMP signaling.Chemotherapy 2018;63:284 –292 (Source: Chemotherapy)
Source: Chemotherapy - February 7, 2019 Category: Cancer & Oncology Source Type: research

Ginsenoside-Rg5 Inhibits Retinoblastoma Proliferation and Induces Apoptosis through Suppressing BCL2 Expression
Conclusion: Ginsenoside-Rg5 inhibits cell proliferation and induces apoptosis in retinoblastoma cells by inactivating the AKT signaling pathway, thereby downregulating BCL2 expression.Chemotherapy 2018;63:293 –300 (Source: Chemotherapy)
Source: Chemotherapy - February 7, 2019 Category: Cancer & Oncology Source Type: research

Combining Tumor-Selective Bacterial Therapy with < b > < i > Salmonella typhimurium < /i > < /b > A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing ’s Sarcoma in a Patient-Derived Orthotopic Xenograft Model
Conclusions: The present results suggest that the combination ofS. typhimurium A1-R and o-rMETase has promise to be a transformative therapy for ES.Chemotherapy 2018;63:278 –283 (Source: Chemotherapy)
Source: Chemotherapy - January 27, 2019 Category: Cancer & Oncology Source Type: research

Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer
Conclusions: In this case, we described recurrence of nivolumab-induced pneumonitis as a serious adverse event in immune checkpoint inhibitors. Our case illustrates that immune-related adverse events may correlate with antitumour activity, even after treatment discontinuation. In addition, this case suggests the possible clinical utility of CEA serum levels for the assessment of (durable) effects of immunotherapy.Chemotherapy 2018;63:272 –277 (Source: Chemotherapy)
Source: Chemotherapy - December 20, 2018 Category: Cancer & Oncology Source Type: research

ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2
This study was designed to investigate the role of ZEB1 and SLC3A2 in the chemoresistance to cisplatin in ovarian cancer cells. We found that ZEB1 was increased in cisplatin-resistant SKOV3/DPP cells. Downregulation of ZEB1 significantly decreased cell viability in response to cisplatin, increased cis ­platin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin. In addition, downregulation of ZEB1 decreased the volume and weight of implanted tumors. SLC3A2 was decreased in cisplatin-resistant SKOV3/DPP cells. Upregulation of SLC3A2 significantly decreased cell via bility in response to c...
Source: Chemotherapy - November 27, 2018 Category: Cancer & Oncology Source Type: research

Small-Cell Lung Cancer Comorbid with Pulmonary < b > < i > Mycobacterium avium < /i > < /b > Infection: A Case Report
Conclusions: Treatments for concurrent SCLC and pulmonary MAC infection may be successfully conducted with discontinuation of CAM and RFP before and after etoposide administration.Chemotherapy 2018;63:257 –261 (Source: Chemotherapy)
Source: Chemotherapy - November 22, 2018 Category: Cancer & Oncology Source Type: research

Isavuconazole: Case Report and Pharmacokinetic Considerations
Invasive fungal disease (IFD) is one of the major causes of morbidity and mortality in immunocompromised patients. Voriconazole (VCZ) and posaconazole (PCZ) remain the most widely used antifungals for the prophylaxis and treatment of IFD. However, VCZ and PCZ are liable for drug-drug interactions and show a pharmacokinetic variability that requires therapeutic drug monitoring (TDM). Isavuconazole (IVZ) is a newest generation triazole antifungal approved for the treatment of invasive aspergillosis (IA) in adult patients and for the treatment of invasive mucormycosis in adult patients for whom treatment with amphotericin B i...
Source: Chemotherapy - November 20, 2018 Category: Cancer & Oncology Source Type: research

Hepatitis B Reactivation Rate Is Higher Undergoing Some Cytotoxic Chemotherapy in Patients with Solid Tumors: A Large Retrospective Study
Conclusion: Increased reactivation rates were detected with usage of 5-FU, cisplatin, cyclophosphamide, doxorubicin, steroid, rituximab, and vincristine.Chemotherapy 2018;63:247 –252 (Source: Chemotherapy)
Source: Chemotherapy - November 8, 2018 Category: Cancer & Oncology Source Type: research

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph ’+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
We report on a young patient affected by Ph’+-ALL, who relapsed after the second HSCT and who reached molecular remission and long-term disease control by treatment with the anti-CD22 monoclonal antibody inotuzumab ozogamicin, DLI, and the 3rd generation TKI ponatinib.Chemotherapy 2018;63:220 –224 (Source: Chemotherapy)
Source: Chemotherapy - October 29, 2018 Category: Cancer & Oncology Source Type: research

Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) continues to be a deadly disease, with only 50 –70% of patients achieving complete remission and less than 30% of adults having sustained long-term remissions. In order to address these unmet medical needs, we carried out a high-throughput screen of an in-house library of on- and off-patent drugs with the OCI/AML-2 cell line. Through this scre en, we discovered adefovir dipi­voxil (adefovir-DP) as being active against human AML. In addition to adefovir-DP, there are second-generation formulations of adefovir, including octadecyloxyethyl adefovir (ODE-adefovir) and hexadecyloxypropyl a...
Source: Chemotherapy - October 29, 2018 Category: Cancer & Oncology Source Type: research

Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen
Conclusions: A primary personalized cardioprotection strategy decreases the number of cardiac deaths and may potentially prolong overall survival in NHL patients with increased risk of anthracycline cardiotoxicity.Chemotherapy 2018;63:238 –245 (Source: Chemotherapy)
Source: Chemotherapy - October 29, 2018 Category: Cancer & Oncology Source Type: research